IP Library › Granted Patent US 11,331,366
Granted Patent B2
US 11,331,366 · App. 16/466,488 · Granted May 17, 2022

Composition for suppressing muscular atrophy

Inventors: Muneshige Shimizu (Osaka, JP); Akina Shiokawa (Osaka, JP); Koichiro Hamada (Osaka, JP); Kiyohiko Magata (Osaka, JP); Takeshi Nikawa (Tokushima, JP); Ayako Maita (Tokushima, JP)
Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
A61K38/05A23L33/18A61K38/06A61P21/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,331,366
App. No.
16/466,488
Granted
May 17, 2022
Kind
B2
Abstract

The present invention provides a composition for suppressing muscular atrophy, comprising as an active ingredient(s) one or more peptides selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; the group consisting of dipeptides comprising F; and the group consisting of dipeptides DI, IY, YN, and NP.

Claims (15)

1. A method for suppressing muscular atrophy, comprising administering to a subject in need thereof one or more peptides selected from

the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; and

the group consisting of dipeptides DI, IF, FN, FY, IY, YN, and NP.

2. The method according to claim 1 , wherein the one or more peptides comprise FN.

3. The method according to claim 1 , for treating a disease with muscular atrophy.

4. The method according to claim 3 , wherein the disease is sarcopenia, disuse muscle atrophy, muscular dystrophy, diabetic amyotrophy, cachexia, steroid myopathy, drug induced myopathy, rhabdomyolysis, myasthenia gravis, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, or stress urinary incontinence.

5. The method according to claim 1 , wherein the one or more peptides are comprised in a pharmaceutical product.

6. The method according to claim 1 , wherein the one or more peptides are included in a food or drink.

7. A method for improving low muscle mass, comprising administering to a subject in need thereof one or more peptides selected from

the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; and

the group consisting of dipeptides DI, IF, FN, FY, IY, YN, and NP.

8. The method according to claim 7 , wherein the one or more peptides comprise FN.

9. The method according to claim 7 , for improving stress urinary incontinence.

10. The method according to claim 7 , for improving urine leakage.

11. The method according to claim 7 , wherein the one or more peptides are comprised in a food or drink.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 9, 2021
From: SHIMIZU, MUNESHIGE; SHIOKAWA, AKINA; HAMADA, KOICHIRO; MAGATA, KIYOHIKO; NIKAWA, TAKESHI; MAITA, AYAKO
To: OTSUKA PHARMACEUTICAL CO., LTD.
Reel/Frame 055194/0512 →
Priority Claims (1)
JP JP2016-236099 · Dec 5, 2016 · national
Continuity (1)
Related Publication 20190314443A1 · Oct 17, 2019